CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
319 Pages
December 2023
Region: Global
Fairfield Market Research
ID: 5918341

The global CMO/CDMO biotechnology market is experiencing unprecedented growth over the next decade. The market's revenue is set to soar from US$ 13 billion in 2024 to an estimated US$ 32 billion by the end of 2031. This remarkable growth is attributed to innovations in biologic manufacturing, increased adoption of contract manufacturing and development services, and expanding opportunities in emerging markets.

Rising Demand for Stand-Alone Services

Throughout the forecast period, the demand for stand-alone services is expected to remain the highest. Contract development and manufacturing organizations (CDMOs) provide critical services to biotechnology and biopharmaceutical companies, encompassing bio-manufacturing, analytical testing, development, clinical supply, fill-finishing, packaging, and more. Stand-alone services hold the largest market share, driven by the expanding cell-line development services in biopharmaceutical and biotechnology industries, accounting for 62.2% of the market.

Technological Advancements and Operational Efficiency

Leading CDMOs are focused on increasing manufacturing capacity while maintaining operational speed and flexibility. Cutting-edge single-use technologies have enabled companies to reduce batch manufacturing and cleaning time significantly. This operational efficiency provides a competitive edge and supports the industry's growth.

Market Growth Drivers

1. Novel Biologic and Biosimilar Manufacturing: The manufacturing of novel biologics and biosimilars offers substantial growth potential for the CMO/CDMO biotechnology market. Scientific advancements in biopharmaceuticals create opportunities for technologically enhanced CDMOs.
2. Adoption of CMO/CDMO Business Models: The adoption of CMO and CDMO business models, along with a focus on reducing operational costs, is driving market growth. Outsourcing R&D and commercialization of biopharmaceuticals to CMOs/CDMOs can enhance operational efficiency.
3. High Costs and Talent Gap: However, the market faces challenges related to the high costs associated with contract manufacturing investments. Additionally, the shortage of highly qualified and experienced professionals hampers growth in some regions.

Booming U.S. Market

The U.S. market is experiencing robust growth due to ongoing merger and acquisition activities among American manufacturers. The preference for single-use bioreactors is on the rise in the biopharmaceutical CDMOs market, supporting the growth of the industry.

Lucrative Prospects in the U.K.

The United Kingdom is expected to become a lucrative market due to expanding applications in gene and cell therapy. Manufacturers in the U.K. are providing top-notch biopharmaceutical contract development and manufacturing services, focusing on global presence and technological capabilities.

South Korea's Emerging Prominence

South Korea is emerging as a prominent market in East Asia, primarily due to its comprehensive range of developmental services, including cell line creation, process development, and formulation analysis methodology.

Competitive Landscape

Key players in the CMO/CDMO biotechnology market are expanding their presence in emerging regions and introducing new products. They are also strengthening their distribution channels, including online sources of advertisement.

Key Companies Profiled:

Patheon N.V.
Catalent
Samsung Biologics Co., Ltd
Lonza
Boehringer Ingelheim
Samsung BioLogics
AGC Biologics, Inc.
WuXi Biologics
AbbVie Inc
Avid Bioservices, Inc.
Fujifilm Diosynth Biotechnologies
Xpress Biologic
Rentschler Biopharma SE
KBI Biopharma (JSR Corporation)
Cytovance Biologics

The CMO/CDMO biotechnology market is poised for substantial growth, driven by technological advancements and the expansion of contract manufacturing and development services. As the industry continues to evolve, these services will play a pivotal role in accelerating the development and production of biopharmaceuticals and biosimilars.

Market Segmentation

By Service:

Stand-Alone Services
Cell-line development
Development and Bio manufacturing
Analytical Services
Fill Finish
Packaging
Clinical Supply Services
Integrated

By Product:

Monoclonal Antibodies
Antibody Fragments
Recombinant Therapeutic Proteins
Viral Vector
Cell and Gene Therapy
Vaccine

By Expression System:

Mammalian
Microbial
Bacteria
Yeast

By Company Size:

Small
Mid-Sized
Large
Very Large

By Scale of Operations:

Pre-clinical
Clinical
Commercial

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global CMO/CDMO Biotechnology Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

3.1. Global CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Stand-Alone Services
3.1.1.1.1. Cell-line development
3.1.1.1.2. Development and Bio manufacturing
3.1.1.1.3. Analytical Services
3.1.1.1.4. Fill Finish
3.1.1.1.5. Packaging
3.1.1.1.6. Clinical Supply Services
3.1.1.2. Integrated
3.2. Global CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Monoclonal Antibodies
3.2.1.2. Antibody Fragments
3.2.1.3. Recombinant Therapeutic Proteins
3.2.1.4. Viral Vector
3.2.1.5. Cell and Gene Therapy
3.2.1.6. Vaccine
3.3. Global CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Mammalian
3.3.1.2. Microbial
3.3.1.2.1. Bacteria
3.3.1.2.2. Yeast
3.4. Global CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Small
3.4.1.2. Mid-Sized
3.4.1.3. Large
3.4.1.4. Very Large
3.5. Global CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. Pre-clinical
3.5.1.2. Clinical
3.5.1.3. Commercial
3.6. Global CMO/CDMO Biotechnology Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa

4. North America CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

4.1. North America CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Stand-Alone Services
4.1.1.1.1. Cell-line development
4.1.1.1.2. Development and Bio manufacturing
4.1.1.1.3. Analytical Services
4.1.1.1.4. Fill Finish
4.1.1.1.5. Packaging
4.1.1.1.6. Clinical Supply Services
4.1.1.2. Integrated
4.2. North America CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Monoclonal Antibodies
4.2.1.2. Antibody Fragments
4.2.1.3. Recombinant Therapeutic Proteins
4.2.1.4. Viral Vector
4.2.1.5. Cell and Gene Therapy
4.2.1.6. Vaccine
4.3. North America CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Mammalian
4.3.1.2. Microbial
4.3.1.2.1. Bacteria
4.3.1.2.2. Yeast
4.4. North America CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Small
4.4.1.2. Mid-Sized
4.4.1.3. Large
4.4.1.4. Very Large
4.5. North America CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. Pre-clinical
4.5.1.2. Clinical
4.5.1.3. Commercial
4.6. North America CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.6.1. Key Highlights
4.6.1.1. U.S. CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
4.6.1.2. U.S. CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
4.6.1.3. U.S. CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
4.6.1.4. U.S. CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
4.6.1.5. U.S. CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
4.6.1.6. Canada CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
4.6.1.7. Canada CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
4.6.1.8. Canada CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
4.6.1.9. Canada CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
4.6.1.10. Canada CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

5.1. Europe CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Stand-Alone Services
5.1.1.1.1. Cell-line development
5.1.1.1.2. Development and Bio manufacturing
5.1.1.1.3. Analytical Services
5.1.1.1.4. Fill Finish
5.1.1.1.5. Packaging
5.1.1.1.6. Clinical Supply Services
5.1.1.2. Integrated
5.2. Europe CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Monoclonal Antibodies
5.2.1.2. Antibody Fragments
5.2.1.3. Recombinant Therapeutic Proteins
5.2.1.4. Viral Vector
5.2.1.5. Cell and Gene Therapy
5.2.1.6. Vaccine
5.3. Europe CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Mammalian
5.3.1.2. Microbial
5.3.1.2.1. Bacteria
5.3.1.2.2. Yeast
5.4. Europe CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Small
5.4.1.2. Mid-Sized
5.4.1.3. Large
5.4.1.4. Very Large
5.5. Europe CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Pre-clinical
5.5.1.2. Clinical
5.5.1.3. Commercial
5.6. Europe CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.6.1. Key Highlights
5.6.1.1. Germany CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.2. Germany CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.3. Germany CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.4. Germany CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.5. Germany CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.6. U.K. CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.7. U.K. CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.8. U.K. CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.9. U.K. CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.10. U.K. CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.11. France CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.12. France CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.13. France CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.14. France CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.15. France CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.16. Italy CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.17. Italy CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.18. Italy CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.19. Italy CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.20. Italy CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.21. Turkey CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.22. Turkey CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.23. Turkey CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.24. Turkey CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.25. Turkey CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.26. Russia CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.27. Russia CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.28. Russia CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.29. Russia CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.30. Russia CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.1.31. Rest of Europe CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
5.6.1.32. Rest of Europe CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
5.6.1.33. Rest of Europe CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
5.6.1.34. Rest of Europe CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
5.6.1.35. Rest of Europe CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

6.1. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Instruments
6.1.1.1.1. Fully CMO/CDMO Biotechnology
6.1.1.1.2. Semi-CMO/CDMO Biotechnology
6.1.1.2. Consumables
6.2. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Stand-Alone Services
6.2.1.1.1. Cell-line development
6.2.1.1.2. Development and Bio manufacturing
6.2.1.1.3. Analytical Services
6.2.1.1.4. Fill Finish
6.2.1.1.5. Packaging
6.2.1.1.6. Clinical Supply Services
6.2.1.2. Integrated
6.3. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Monoclonal Antibodies
6.3.1.2. Antibody Fragments
6.3.1.3. Recombinant Therapeutic Proteins
6.3.1.4. Viral Vector
6.3.1.5. Cell and Gene Therapy
6.3.1.6. Vaccine
6.4. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Mammalian
6.4.1.2. Microbial
6.4.1.2.1. Bacteria
6.4.1.2.2. Yeast
6.5. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. Small
6.5.1.2. Mid-Sized
6.5.1.3. Large
6.5.1.4. Very Large
6.6. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
6.6.1. Key Highlights
6.6.1.1. Pre-clinical
6.6.1.2. Clinical
6.6.1.3. Commercial
6.7. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.7.1. Key Highlights
6.7.1.1. China CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.2. China CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.3. China CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.4. China CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.5. China CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.1.6. Japan CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.7. Japan CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.8. Japan CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.9. Japan CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.10. Japan CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.1.11. South Korea CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.12. South Korea CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.13. South Korea CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.14. South Korea CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.15. South Korea CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.1.16. India CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.17. India CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.18. India CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.19. India CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.20. India CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.1.21. Southeast Asia CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.22. Southeast Asia CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.23. Southeast Asia CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.24. Southeast Asia CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.25. Southeast Asia CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.1.26. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
6.7.1.27. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
6.7.1.28. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
6.7.1.29. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
6.7.1.30. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.7.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

7.1. Latin America CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Stand-Alone Services
7.1.1.1.1. Cell-line development
7.1.1.1.2. Development and Bio manufacturing
7.1.1.1.3. Analytical Services
7.1.1.1.4. Fill Finish
7.1.1.1.5. Packaging
7.1.1.1.6. Clinical Supply Services
7.1.1.2. Integrated
7.2. Latin America CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Monoclonal Antibodies
7.2.1.2. Antibody Fragments
7.2.1.3. Recombinant Therapeutic Proteins
7.2.1.4. Viral Vector
7.2.1.5. Cell and Gene Therapy
7.2.1.6. Vaccine
7.3. Latin America CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Mammalian
7.3.1.2. Microbial
7.3.1.2.1. Bacteria
7.3.1.2.2. Yeast
7.4. Latin America CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Small
7.4.1.2. Mid-Sized
7.4.1.3. Large
7.4.1.4. Very Large
7.5. Latin America CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Pre-clinical
7.5.1.2. Clinical
7.5.1.3. Commercial
7.6. Latin America CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.6.1. Key Highlights
7.6.1.1. Brazil CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
7.6.1.2. Brazil CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
7.6.1.3. Brazil CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
7.6.1.4. Brazil CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
7.6.1.5. Brazil CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.6.1.6. Mexico CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
7.6.1.7. Mexico CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
7.6.1.8. Mexico CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
7.6.1.9. Mexico CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
7.6.1.10. Mexico CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.6.1.11. Argentina CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
7.6.1.12. Argentina CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
7.6.1.13. Argentina CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
7.6.1.14. Argentina CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
7.6.1.15. Argentina CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.6.1.16. Rest of Latin America CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
7.6.1.17. Rest of Latin America CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
7.6.1.18. Rest of Latin America CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
7.6.1.19. Rest of Latin America CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
7.6.1.20. Rest of Latin America CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, 2018 - 2031

8.1. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Instruments
8.1.1.1.1. Fully CMO/CDMO Biotechnology
8.1.1.1.2. Semi-CMO/CDMO Biotechnology
8.1.1.2. Consumables
8.2. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Stand-Alone Services
8.2.1.1.1. Cell-line development
8.2.1.1.2. Development and Bio manufacturing
8.2.1.1.3. Analytical Services
8.2.1.1.4. Fill Finish
8.2.1.1.5. Packaging
8.2.1.1.6. Clinical Supply Services
8.2.1.2. Integrated
8.3. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Monoclonal Antibodies
8.3.1.2. Antibody Fragments
8.3.1.3. Recombinant Therapeutic Proteins
8.3.1.4. Viral Vector
8.3.1.5. Cell and Gene Therapy
8.3.1.6. Vaccine
8.4. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Mammalian
8.4.1.2. Microbial
8.4.1.2.1. Bacteria
8.4.1.2.2. Yeast
8.5. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. Small
8.5.1.2. Mid-Sized
8.5.1.3. Large
8.5.1.4. Very Large
8.6. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2018 - 2031
8.6.1. Key Highlights
8.6.1.1. Pre-clinical
8.6.1.2. Clinical
8.6.1.3. Commercial
8.7. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.7.1. Key Highlights
8.7.1.1. GCC CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
8.7.1.2. GCC CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
8.7.1.3. GCC CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
8.7.1.4. GCC CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
8.7.1.5. GCC CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.7.1.6. South Africa CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
8.7.1.7. South Africa CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
8.7.1.8. South Africa CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
8.7.1.9. South Africa CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
8.7.1.10. South Africa CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.7.1.11. Egypt CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
8.7.1.12. Egypt CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
8.7.1.13. Egypt CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
8.7.1.14. Egypt CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
8.7.1.15. Egypt CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.7.1.16. Nigeria CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
8.7.1.17. Nigeria CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
8.7.1.18. Nigeria CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
8.7.1.19. Nigeria CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
8.7.1.20. Nigeria CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.7.1.21. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2018 - 2031
8.7.1.22. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2018 - 2031
8.7.1.23. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2018 - 2031
8.7.1.24. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2018 - 2031
8.7.1.25. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.7.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Service vs Product Heatmap
9.2. Manufacturer vs Product Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Patheon N.V.
9.5.1.1. Company Overview
9.5.1.2. Service Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Catalent
9.5.2.1. Company Overview
9.5.2.2. Service Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Samsung Biologics Co., Ltd
9.5.3.1. Company Overview
9.5.3.2. Service Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Lonza.
9.5.4.1. Company Overview
9.5.4.2. Service Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Boehringer Ingelheim
9.5.5.1. Company Overview
9.5.5.2. Service Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Samsung BioLogics
9.5.6.1. Company Overview
9.5.6.2. Service Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. AGC Biologics, Inc.
9.5.7.1. Company Overview
9.5.7.2. Service Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. WuXi Biologics
9.5.8.1. Company Overview
9.5.8.2. Service Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. AbbVie Inc
9.5.9.1. Company Overview
9.5.9.2. Service Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Avid Bioservices, Inc.
9.5.10.1. Company Overview
9.5.10.2. Service Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Fujifilm Diosynth Biotechnologies
9.5.11.1. Company Overview
9.5.11.2. Service Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Xpress Biologic
9.5.12.1. Company Overview
9.5.12.2. Service Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Rentschler Biopharma SE
9.5.13.1. Company Overview
9.5.13.2. Service Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. KBI Biopharma (JSR Corporation)
9.5.14.1. Company Overview
9.5.14.2. Service Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.14.5. Business Strategies and Development
9.5.15. Cytovance Biologics
9.5.15.1. Company Overview
9.5.15.2. Service Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Patheon N.V.
Catalent
Samsung Biologics Co., Ltd
Lonza.
Boehringer Ingelheim
Samsung BioLogics
AGC Biologics, Inc.
WuXi Biologics
AbbVie Inc
Avid Bioservices, Inc.
Fujifilm Diosynth Biotechnologies
Xpress Biologic
Rentschler Biopharma SE
KBI Biopharma (JSR Corporation)
Cytovance Biologics

Methodology

LOADING...

Rising Demand for Stand-Alone Services

Technological Advancements and Operational Efficiency

Market Growth Drivers

Booming U.S. Market

South Korea's Emerging Prominence

Competitive Landscape

Key Companies Profiled:

Market Segmentation

By Service:

By Product:

By Expression System:

By Company Size:

By Scale of Operations:

By Region:

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Small Molecule CMO/CDMO Global Market Report 2024

Cosmetic CDMO Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets

Small Molecule Innovator CDMO Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031